SEARCH

SEARCH BY CITATION

References

  • 1
    Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006; 144: 762769.
  • 2
    Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002; 92: 17891794.
  • 3
    U.S. Department of Justice. Prison and jail inmates at midyear 2006. Bureau of Justice Statistics Bulletin, June 2007. Available at: http://www.ojp.usdoj.gov/bjs/abstract/pjim06.htm. Accessed July 2008.
  • 4
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 15621569.
  • 5
    Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Morb Mortal Wkly Rep 2003; 52(RR-1): 136.
  • 6
    Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS 2005; 19(Suppl 3): S41S46.
  • 7
    Fox RK, Currie SL, Evans J, Wright TL, Tobler L, Phelps B, et al. Hepatitis C virus infection among prisoners in the California State Correctional System. Clin Infect Dis 2005; 41: 177186.
  • 8
    Hammett TM. Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med 2003; 138: 235236.
  • 9
    Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med 1999; 28: 92100.
  • 10
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228237.
  • 11
    Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425432.
  • 12
    Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, et al. A health economic model to assess the cost-effectiveness of PEG IFN α-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat 2007; 14: 523536.
  • 13
    Lidgren M, Hollander A, Weiland O, Jönsson B. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. Scand J Gastroenterol 2007; 42: 867877.
  • 14
    Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis 2006; 38: 497505.
  • 15
    Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687694.
  • 16
    Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 257265.
  • 17
    Annemans L, Warie H, Nechelput M, Peraux B. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol Belg 2004; 67: 18.
  • 18
    Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99: 14901496.
    Direct Link:
  • 19
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iiiiv, 1–125.
  • 20
    Hornberger J, Farci P, Prati D, Zeuzem S, Green J, Patel KK. The economics of treating chronic hepatitis C patients with peginterferon α-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. J Viral Hepat 2006; 13: 377386.
  • 21
    Lin WA, Tarn YH, Tang SL. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C. Aliment Pharmacol Ther 2006; 24: 14831493.
  • 22
    Yeh WS, Armstrong EP, Skrepnek GH, Malone DC. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy 2007; 27: 813824.
  • 23
    Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost-effectiveness of interferon-alpha or peg-interferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55: 13321338.
  • 24
    U.S. Department of Justice. Prison and jail inmates at midyear 2005. Bureau of Justice Statistics Bulletin, May 2006. Available at: http://www.ojp.usdoj.gov/bjs/abstract/pjim05.htm. Accessed July 2008.
  • 25
    Sterling RK, Brown RS, Hofmann CM, Luketic VA, Stravits RT, Sanyal AJ, et al. The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. Am J Gastroenterol 2005; 100: 313321.
    Direct Link:
  • 26
    Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138: 187190.
  • 27
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372374.
  • 28
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 15131520.
  • 29
    Kim AI, Saab S. Treatment of hepatitis C. Am J Med 2005; 118: 808815.
  • 30
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 11471171.
  • 31
    Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al, and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358; 958-;965.
  • 32
    Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347; 975982.
  • 33
    Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346355.
  • 34
    Centers for Disease Control. United States life tables, 2003. National Vital Statistics Reports, April 2006. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/life/1966.htm. Accessed July 2008.
  • 35
    Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—a high risk of death for former inmates. N Engl J Med 2007; 356: 157165.
  • 36
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzela G, et al. Sustained virological response to inteferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579587.
  • 37
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677684.
  • 38
    National HCV Prison Coalition. State-by-state HCV treatment guidelines. Available at: http://www.hcvinprison.org. Accessed July 2008.
  • 39
    Federal Bureau of Prisons. Guidelines for the prevention and treatment of viral hepatitis. Federal Bureau of Prisons—Clinical Practice Guidelines, October 2005. Available at: http://www.bop.gov/news/PDFs/hepatitis.pdf. Accessed July 2008.
  • 40
    Baillargeon J, Soloway RD, Paar D, Giordano TP, Murray O, Grady J, et al. End-stage liver disease in a state prison population. Ann Epidemiol 2007; 17: 808813.
  • 41
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855865.
  • 42
    Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health 2004; 94: 12181223.
  • 43
    Vlahov D, Nelson KE, Quinn TC, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol 1993; 9: 566569.
  • 44
    Armstrong GL, Alter MJ, McQuillan GM, Margold HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. HEPATOLOGY 2000; 31: 777782.
  • 45
    Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. Ann Intern Med 2000; 133: 655675.
  • 46
    Wright M, Grieve R, Roberts J, Main J, Thomas HC, on behalf of the UK Mild Hepatitis C Trial Investigators. Health benefits of antivital therapy for mild chronic hepatitis C: randomized controlled trial and economic evaluation. Health Technol Assess 2006; 10: 1113, iii.
  • 47
    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999; 30: 13181324.
  • 48
    Drug Topics Red Book. Montvale, NJ: Medical Economics; 2007.
  • 49
    U.S. Department of Labor Bureau of Labor Statistics. Consumer price index calculator. Available at: http://www.bls.gov. Accessed July 2008.
  • 50
    Hoover D, Crystal S, Kumar R. Medical expenditures during the last year of medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002; 37: 16251642.
  • 51
    Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits and costs. JAMA 1998; 280: 20882093.
  • 52
    Conjeevaram HS, Fried MW, Jeffers IJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470477.
  • 53
    Sterling RK, Hoffman CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: can compliance overcome racial differences to response? Am J Gastroenterol 2004; 99: 866872.
    Direct Link:
  • 54
    Kraus MR, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I, Scheurlen M. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, double-blind, placebo-controlled study. Gut 2008; 57: 531536.
  • 55
    Internet Drug News.com. Antidepressants drug database. Available at: http://www.coreynahman.com/antidepressantdrugsdatabase.html. Accessed July 2008.
  • 56
    U.S. Department of Justice. Mental health problems of prison and jail inmates. Bureau of Justice Statistics Special Report, September 2006. Available at: http://www.ojp.gov/bjs/pub/pdf/mhppji.pdf. Accessed July 2008.
  • 57
    Thein HH, Butler TO, Krahn M, Rawlinson W, Levy MH, Kaldor JM, et al. The effect of hepatitis C virus infection on health-related quality of life in prisoners. J Urban Health 2006; 83: 275288.
  • 58
    U.S. Department of Justice. Hepatitis testing and treatment in state prisons. Bureau of Justice Statistics Special Report, April 2004. Available at: http://www.ojp.usdoj.gov/bjs/pub/pdf/httsp.pdf. Accessed July 2008.
  • 59
    Gustafson, Alan. Lawsuit spurs top-rank care to fight disease. Statesman Journal [serial online], Nov. 12, 2007. Available at: http://www.statesmanjournal.com/apps/pbcs.dll/article?AID=/20071112/NEWS/711120329/100. Accessed December 17, 2007.
  • 60
    The body. The complete HIV/AIDS resource. Available at: http://www.thebody.com/content/art31262.html#hcv_inmates. Accessed July 2008.